Sutro Biopharma has dosed the first patient in a Phase I clinical trial of anti-folate receptor alpha (FoIRα) antibody-drug conjugate (ADC) STRO-002 to treat patients with ovarian and endometrial cancers.

This is the second product candidate to be evaluated resulting from Sutro’s XpressCF+ technology platform, which initially led to the discovery of STRO-001.

In April last year, Sutro started dosing patients in a Phase I clinical trial of STRO-001 to treat lymphoma and multiple myeloma.

The multi-centre, open-label, dose-escalation with dose expansion Phase I trial will evaluate the safety, tolerability and preliminary anti-tumour activity of STRO-002.

“Our goal is to ultimately help fill the unmet need for more targeted therapies for patients with ovarian and endometrial cancer.”

As part of the study, up to 160 women with advanced relapsed and / or progressive ovarian, fallopian, primary peritoneal or endometrial cancer will be enrolled.

Sutro Biopharma CEO Bill Newell said: “Moving our second product candidate into human clinical trials is another momentous milestone in Sutro’s evolution from a technology platform company to a clinical stage company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our goal is to ultimately help fill the unmet need for more targeted therapies for patients with ovarian and endometrial cancer and advancing STRO-002 into the clinic brings us one step closer to achieving this.”

In preclinical studies, STRO-002 demonstrated potent in vitro cytotoxicity in ovarian cancer cell lines and inhibited tumour growth in multiple ovarian cancer xenograft models.

Safety studies conducted in non-human primates showed that STRO-002 was well tolerated at clinically relevant doses.

The Phase I study will comprise dose-escalation followed by dose-expansion, as part of which STRO-002 will be dosed as an intravenous infusion on day one of 21-day cycles.

Sutro developed STRO-002 using proprietary cell-free protein synthesis and site-specific conjugation platforms.